
|Articles|August 13, 2008
FDA warns of adverse reactions to naltrexone
The FDA said patients should monitor the injection site.
Advertisement
The Food and Drug Administration is
The FDA said patients should monitor the injection site and contact a physician if they develop pain, swelling, tenderness, induration, bruising, pruritus, or redness that does not improve or worsens within two weeks.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
CDC Will Focus on BA.2.3 COVID-19 Variant for Upcoming Respiratory Season
2
Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides
3
HHS Using AI Initiative to Uncover Health Care Fraud, Waste
4
GLP-1s Could Replace the Need for Knee Replacement Surgery
5



















































